49
Participants
Start Date
February 28, 2010
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
5-FU
IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
Leucovorin
IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
5-FU
IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
Irinotecan
IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
Brivanib
Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
Brivanib
Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
Brivanib
Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
Texas Oncology, Dallas
Scott & White Memorial Hospital And Clinic, Temple
Usc/Norris Comprehensive Cancer Center, Los Angeles
Local Institution, Villejuif
Local Institution, Edmonton
Local Institution, Ottawa
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY